Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

February 14, 2016 4:46 PM ET


Company Overview of Avid Radiopharmaceuticals, Inc.

Company Overview

Avid Radiopharmaceuticals, Inc. develops molecular imaging agents for the medical management of chronic human diseases by identifying the first stages of pathological change. The company was founded in 2004 and is based in Philadelphia, Pennsylvania. As of December 20, 2010, Avid Radiopharmaceuticals, Inc. operates as a subsidiary of Eli Lilly and Company.

3711 Market Street

7th Floor

Philadelphia, PA 19104

United States

Founded in 2004





Key Executives for Avid Radiopharmaceuticals, Inc.

Founder, Chief Executive Officer, President and Director
Chief Scientific Advisor and Chairman of the Scientific Advisory Board
Chief Medical Officer
Vice President of Clinical Development
Vice President of Chemical Development and Manufacturing
Compensation as of Fiscal Year 2015.

Avid Radiopharmaceuticals, Inc. Key Developments

Eli Lilly and Company and Avid Radiopharmaceuticals, Inc. Announce Financial Commitment and Continued Scientific Partnership

Eli Lilly and Company and Avid Radiopharmaceuticals, Inc. announced financial commitment and continued scientific partnership to support the recently established Imaging Dementia 'Evidence for Amyloid Scanning (IDEAS) Study'. The IDEAS Study will assess the clinical usefulness and value in using an amyloid brain positron emission tomography (PET) scan in certain situations when evaluating Alzheimer's disease (AD) and other dementias. Amyvid™ (Florbetapir F-18 Injection), Lilly's FDA-approved radioactive PET diagnostic agent for the estimation of beta-amyloid neuritic plaque density in the brain, will be one diagnostic agent available for use in the study. Manufactured in and distributed from 30 radiopharmacy facilities throughout the United States, Amyvid is currently supplied to a robust network of PET imaging sites by Siemens' PETNET Solutions and Cardinal Health. Amyvid for intravenous use is supplied in 10 mL, 30 mL, or 50 mL multidose vials containing 500-1900 MBq/mL Florbetapir F-18.

Similar Private Companies By Industry

Company Name Region
Pathogen Removal and Diagnostic Technologies, Inc. United States
Target Discovery, Inc. United States
QIAGEN North American Holdings, Inc. United States
Genomic Expression Inc. United States
Strategic Science & Technologies, LLC United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Avid Radiopharmaceuticals, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at